Advisors Preferred LLC raised its position in shares of Novo Nordisk A/S (NYSE:NVO) by 505.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,797 shares of the company’s stock after acquiring an additional 1,500 shares during the quarter. Advisors Preferred LLC’s holdings in Novo Nordisk A/S were worth $104,000 as of its most recent SEC filing.
A number of other institutional investors have also modified their holdings of NVO. Keeler Thomas Management LLC raised its position in shares of Novo Nordisk A/S by 3.0% in the 4th quarter. Keeler Thomas Management LLC now owns 15,550 shares of the company’s stock worth $900,000 after acquiring an additional 450 shares in the last quarter. Janney Montgomery Scott LLC boosted its position in shares of Novo Nordisk A/S by 12.7% during the 4th quarter. Janney Montgomery Scott LLC now owns 85,272 shares of the company’s stock valued at $4,936,000 after purchasing an additional 9,629 shares in the last quarter. Squar Milner Financial Services LLC boosted its position in shares of Novo Nordisk A/S by 11.5% during the 4th quarter. Squar Milner Financial Services LLC now owns 12,480 shares of the company’s stock valued at $722,000 after purchasing an additional 1,283 shares in the last quarter. Manchester Financial Inc. acquired a new stake in Novo Nordisk A/S during the fourth quarter worth approximately $26,000. Finally, Huntington National Bank grew its stake in Novo Nordisk A/S by 31.8% during the fourth quarter. Huntington National Bank now owns 7,213 shares of the company’s stock worth $417,000 after purchasing an additional 1,742 shares during the period. Hedge funds and other institutional investors own 7.26% of the company’s stock.
Shares of NVO opened at $61.14 on Wednesday. Novo Nordisk A/S has a one year low of $46.10 and a one year high of $62.69. The company has a market cap of $145.18 billion, a PE ratio of 24.96, a P/E/G ratio of 2.26 and a beta of 0.60. The stock has a 50-day moving average of $58.14 and a 200-day moving average of $53.66. The company has a debt-to-equity ratio of 0.06, a current ratio of 1.00 and a quick ratio of 0.73.
Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings results on Friday, November 1st. The company reported $0.64 earnings per share for the quarter, topping analysts’ consensus estimates of $0.62 by $0.02. The business had revenue of $4.51 billion for the quarter, compared to the consensus estimate of $4.55 billion. Novo Nordisk A/S had a return on equity of 75.48% and a net margin of 32.44%. Analysts expect that Novo Nordisk A/S will post 2.45 EPS for the current fiscal year.
NVO has been the topic of several recent analyst reports. UBS Group lowered Novo Nordisk A/S from a “buy” rating to a “neutral” rating in a research note on Monday, November 18th. ValuEngine cut Novo Nordisk A/S from a “hold” rating to a “sell” rating in a report on Tuesday, January 14th. Barclays raised shares of Novo Nordisk A/S from an “equal weight” rating to an “overweight” rating in a research report on Wednesday, November 27th. Pareto Securities lowered shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Friday, November 22nd. Finally, Guggenheim downgraded shares of Novo Nordisk A/S from a “buy” rating to a “neutral” rating in a research report on Friday, January 3rd. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and four have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $159.65.
Novo Nordisk A/S Profile
Novo Nordisk A/S, a healthcare company, engages in the development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral anti-diabetic products, obesity, and other chronic diseases.
See Also: What is a portfolio manager?
Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO).
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.